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Abstract
Recently it was found that prior immunization with recombinant rabies virus (RABV) expressing granulocyte-macrophage
colony-stimulating factor (GM-CSF) (LBNSE-GM-CSF) resulted in high innate/adaptive immune responses and protection
against challenge with virulent RABV (Wen et al., JVI, 2011). In this study, the ability of LBNSE-GM-CSF to prevent animals
from developing rabies was investigated in mice after infection with lethal doses of street RABV. It was found that
intracerebral administration of LBNSE-GM-CSF protected more mice from developing rabies than sham-treated mice as late
as day 5 after infection with street RABV. Intracerebral administration of LBNSE-GM-CSF resulted in significantly higher levels
of chemokine/cytokine expression and more infiltration of inflammatory and immune cells into the central nervous system
(CNS) than sham-administration or administration with UV-inactivated LBNSE-GM-CSF. Enhancement of blood-brain barrier
(BBB) permeability and increases in virus neutralizing antibodies (VNA) were also observed in mice treated with LBNSE-GM-
CSF. On the other hand, intracerebral administration with UV-inactivated LBNSE-GM-CSF did not increase protection despite
the fact that VNA were induced in the periphery. However, intracerebral administration with chemoattractant protein-1
(MCP-1, also termed CCL2) increased significantly the protective efficacy of UV-inactivated LBNSE-GM-CSF. Together these
studies confirm that direct administration of LBNSE-GM-CSF can enhance the innate and adaptive immunity as well as the
BBB permeability, thus allowing infiltration of inflammatory cells and other immune effectors enter into the CNS to clear the
virus and prevent the development of rabies.
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Introduction
Rabies is one of the oldest zoonotic diseases and today it
continues to present a serious burden to the public health and the
global economy. It causes more than 55,000 human deaths and
more than 15 million people undergo post-exposure prophylaxis
(PEP) every year around the globe 1], which is responsible for 1.74
million disability adjusted life year score (DALYs) lost 2]. Most of
the human cases occur in the developing countries of Asia and
Africa where canine rabies is endemic and resources are limited 3].
In more developed countries, human rabies has dramatically
declined during the past 60 years as a direct consequence of
routine vaccination of pet animals 4]. However, wildlife rabies has
emerged as a major threat. In the United States, more than 90%
of animal rabies cases have been reported in wildlife such as
raccoons, bats, skunks and foxes 5,6]. Although there have been
incidents in which large carnivores transmit rabies directly to
humans 7,8], most of the human cases (.90%) in the past two
decades are associated with rabies virus (RABV) found in bats,
particularly the silver-haired bats (SHBRV) 8,9,10]. Unlike
classical rabies, which is inflicted by the bite of an infected
animal, these newly emerging human rabies infections occurred
without a known history of exposure 8]. As a result, PEP with
vaccines and anti-rabies immunoglobulin could not be initiated.
This combined treatment is effective when it is initiated within a
few days (but as soon as possible) 11]. However, delayed treatment
with rabies vaccines currently in use may actually accelerate the
development of rabies 12]. It is widely accepted that there is no
proven effective treatment and rabies is almost invariably fatal
once clinical symptoms of rabies develop 12]. Thus new modalities
are needed to prevent and treat clinical rabies.
Recently it was found that activation of the innate immunity,
particularly type I interferon (IFN) and chemokines, is one of the
mechanisms by which RABV is attenuated 13]. Furthermore,
infection with rRABV expressing chemokines/cytokines resulted
in further attenuation of viral virulence and enhancement of
innate and adaptive immunity by inducing the expression of innate
immune molecules, the infiltration of inflammatory cells into the
CNS, and the enhancement of BBB permeability 14]. For
example, prior immunization with rRABV expressing chemo-
kines/cytokines MDC (macrophage-derived chemokine) or GM-
CSF (granulocyte-macrophage colony-stimulating factor) induced
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protection than with the parent virus when challenged with
virulent RABV 15,16]. Yet, these rRABVs did not induce any
overt disease or death in adult mice when 10
7 fluorescent focus
unit (FFU) was directly inoculated by the intracerebral (ic) route
16]. In the present study, rRABV expressing GM-CSF (LBNSE-
GM-CSF) was used to treat mice at different days after an
intramuscular infection with a lethal dose of street RABV. It was
found that direct intracerebral administration of LBNSE-GM-
CSF could induce innate and adaptive immune responses,
allowing immune effectors enter into the CNS to clear the virus
and prevent the development of rabies as late as 5 days after
infection.
Results
Treatment with LBNSE-GM-CSF can prevent mice from
developing rabies as late as 5 days after infection with
street RABV
Our previous studies indicated that rRABVs expressing
chemokines/cytokines, e.g. GM-CSF or MDC, activate/recruit
DCs and enhance protective immune responses when given before
challenge 16]. To investigate whether these rRABVs could prevent
mice from developing rabies when administered after challenge,
ICR mice were inoculated by intramuscular (im) route with 10
50% intramuscular mouse lethal dose (IMLD50) of street RABV
(DRV) and then treated with 10
7 FFU of LBNSE-GM-CSF by ic
route at 2, 4, 5, and 6 days post infection (dpi). Mice were
monitored daily for 20 days for developing disease and death. By
dpi 6 to 8, animals began to develop clinical sign such as ruffled
fur; trembling and shaking; incoordinated movement; and
paralysis. Mice were humanely sacrificed when developing
complete paralysis by dpi 10 to 13. As shown in Fig. 1A, 80%
of the mice infected with DRV by im, but treated with medium by
ic at 2 dpi developed rabies and succumbed to infection by 14 dpi.
None of DRV-infected mice developed any clinical symptom
when treated by ic with LBNSE-GM-CSF at 2 dpi. Significantly
more mice (70%) survived the infection when treated with
LBNSE-GM-CSF at 4 dpi (p,0.01). When the treatment was
initiated at 5 dpi, 60% of the mice survived and this is significant
when compared to shamed-treated. When the treatment was
initiated at 6 dpi, 40% of the mice were protected, but no
significant difference was found when compared with sham-
treated mice. These data indicate that LBNSE-GM-CSF can
prevent mice from developing rabies when administered ic as late
as 5 dpi. To further investigate if ic administration of UV-
inactivated LBNSE-GM-CSF has the same ability to prevent
animals from developing rabies, mice were infected with DRV and
treated with the same amount (equivalent to 10
7 FFU) of UV-
inactivated LBNSE-GM-CSF at 4 dpi. (Fig. 1E). No significantly
more protection was observed in mice treated with UV-inactivated
LBNSE-GM-CSF than in sham-treated mice, indicating that
treatment with UV-inactivated virus is not able to prevent rabies
in the mouse model.
To address if the LBNSE-GM-CSF is also efficacious when
administered by other routes, mice were infected by im with 10
IMLD50 DRV and treated with 10
7 FFU LBNSE-GM-CSF at 0,
2, or 4 dpi by im (Fig. 1B), intradermal (Fig. 1C) or intranasal
(Fig. 1D) route. All the infected and sham-treated mice died while
no mortality was observed in mice when LBNSE-GM-CSF was
administrated at 0 dpi by each route. Significantly more protection
(p,0.01 or p,0.05) was observed when mice were treated at 2 dpi
(40–50%). No significant protection was observed when treatment
was initiated by 4 dpi, indicating that peripheral route is not as
effective as the ic route of administration for treatment with
LBNSE-GM-CSF.
Treatment with LBNSE-GM-CSF cleared RABV from the
CNS
To investigate if treatment with LBNSE-GM-CSF leads to
virus clearance from the CNS, DRV-infected mice were treated
ic at 4 dpi with 10
7 FFU LBNSE-GM-CSF or UV-inactivated
LBNSE-GM-CSF (equivalent to 10
7 FFU). Brains were harvested
and virus titers determined at days 3, 6, 9 after treatment
(Table 1). Higher virus titers were detected in the sham-treated
mice or mice treated with UV-inactivated LBNSE-GM-CSF at
day 6 and 9 post treatment. In LBNSE-GM-CSF-treated group,
virus was detected in all three mice at day 3, none at day 6, and
only one mouse at day 9 post treatment (with low titer). These
data indicate that treatment with LBNSE-GM-CSF not only
results in clearance of the recombinant virus, but also street
RABV from the CNS.
Treatment with LBNSE-GM-CSF induced expression of
chemokines and cytokines in the brain
To determine the mechanism(s) by which treatment with
LBNSE-GM-CSF clears RABV from the brain, the expression
of chemokine and cytokine (MIP-1 alpha, RANTES, IP-10, MCP-
1, IL-6, and IFN-gamma) mRNA was measured by qRT-PCR in
the brain. In mice infected with DRV and treated with LBNSE-
GM-CSF at the same time (Fig. 2A), the expression level of all
these chemokines/cytokines was highly up-regulated at day 3 post
treatment. By day 6 post treatment, the expression level for most of
these chemokines/cytokines was reduced drastically although
remained significantly higher than in mice sham-treated or treated
with UV-inactivated LBNSE-GM-CSF. However, the level of
RANTES expression remained elevated and the level of IFN-
gamma expression reached a peak by day 6 post treatment. By day
9 post treatment, only RANTES remains at high level in mice
infected with DRV and treated with LBNSE-GM-CSF. On the
other hand, high levels of IP-10, MCP-1, and IL-6 were detected
in mice infected with DRV, but sham-treated, by day 9 post
treatment.
When the treatment was initiated at 4 dpi, the expression level
of chemokines/cytokines was significantly higher in the brain of
mice treated with LBNSE-GM-CSF than in mice sham-treated or
treated with UV-inactivated LBNSE-GM-CSF (Fig. 2B) at day 3
post treatment. By days 6 and 9 post treatment (10 and 13 dpi),
however, significantly higher levels of chemokines, particularly
MIP-1 alpha, IP-10 and MCP-1 were detected in the brain of mice
sham-treated or treated with UV-inactivated LBNSE-GM-CSF
than in mice treated with live LBNSE-GM-CSF. For RANTES
and IFN-gamma, the level was significantly higher in mice treated
with LBNSE-GM-CSF at day 6, but not at day 9 post treatment.
Overall, these data indicate that direct ic administration of
LBNSE-GM-CSF is capable of inducing high and transient
expression of chemokines/cytokines in the CNS at day 3 post
treatment (early innate immune responses). On the other hand,
DRV only is capable of inducing expression of chemokine/
cytokine at late stage of infection (9 dpi or later). Direct ic
administration of UV-inactivated LBNSE-GM-CSF does not
induce chemokine/cytokine expression.
Treatment with LBNSE-GM-CSF induced infiltration of
inflammatory cells into the mouse brain
To investigate if expression of chemokins/cytokines leads to
infiltration of inflammatory cells into the CNS, flow cytometry
Recombinant RABV Prevents Rabies
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25414Recombinant RABV Prevents Rabies
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25414was performed to analyze the leukocytes infiltrated into the
mouse brain at days 3, 6, 9 post treatment. Fig. 3A shows
representative flow cytometric plots of neutrophils (Ly6G+ and
CD45+), activated microglia/macrophages (CD11b+ and
CD45+) and CD3+ T cells (CD3+ and CD45+) from brain of
mice infected with DRV and treated with LBNSE-GM-CSF.
Detailed data are presented in Fig. 3B for mice infected with
DRV and treated at the same time and in Fig. 3C for mice
infected with DRV and treated at 4 dpi. Significantly more
infiltration of activated microglia/macrophages (p,0.01), neu-
trophils (p,0.01) and CD3+ T cells (p,0.01) was observed in
mice infected with DRV and treated with LBNSE-GM-CSF than
in mice infected with DRV and sham-treated or treated with UV-
inactivated LBNSE-GM-CSF at days 3, 6, 9 post treatment
(Fig. 3B, 3C). These data indicate that inflammatory cells were
trafficking to and accumulating in the CNS of mice treated with
live LBNSE-GM-CSF.
Treatment with LBNSE-GM-CSF resulted in the
enhancement of BBB permeability
Previous studies have demonstrated that enhancement of BBB
permeability is one of the important mechanisms by which the
immune effectors can enter into the CNS to clear RABV
17,18,19]. To investigate if treatment with LBNSE-GM-CSF
enhances BBB permeability, the leakage of sodium fluorescein
(NaF) from the circulation into CNS tissues was measured in the
cerebrum, cerebellum or spinal cord at day 6 post treatment. As
shown in Fig. 4A, BBB permeability to NaF was significantly
elevated in the cerebrum and cerebellum of mice treated with
LBNSE-GM-CSF with or without prior infection with DRV when
compared with that in sham-treated mice or in mice treated with
UV-inactivated LBNSE-GM-CSF. When the treatment was
initiated 4 dpi, significantly more increase in BBB permeability
was detected in the cerebrum of mice treated with LBNSE-GM-
CSF than in mice sham-treated or treated with UV-inactivated
LBNSE-GM-CSF (Fig. 4B). On the other hand, BBB permeability
of mice infected with DRV without treatments or treated with
UV-inactivated LBNSE-GM-CSF was enhanced. These data
indicate that indeed treatment with LBNSE-GM-CSF enhances
the BBB permeability in the CNS (cerebrum and cerebellum) at
day 6 post treatment. Street RABV alone is only capable of
enhancing the BBB permeability in the spinal cord at late stage of
infection (10 dpi).
Treatment with LBNSE-GM-CSF resulted in recruitment/
activation of DCs and B cells
To investigate if stimulation of innate immunity (expression of
chemokines/cytokines and infiltration of inflammatory cells)
enhances the adaptive immunity, the recruitment/activation of
DCs and B cells was analyzed by flow cytometry using antibodies
to cell surface markers (CD11c, CD86 and CD80 for activated
DCs, CD19 and CD40 for B cells). Fig. 5 shows recruitment/
activation of DC in mice infected and treated at the same time
(Fig. 5A) or treated at 4 dpi (Fig. 5B). Significantly more DCs
(CD11c+) were detected at days 3 and 6 post treatment in mice
treated with LBNSE-GM-CSF than in sham-treated mice or mice
treated with UV-inactivated LBNSE-GM-CSF. Expression level of
activated DC markers (CD80 and CD86) was significantly up-
regulated at days 3 and 6 post treatment in mice treated with
LBNSE-GM-CSF than in sham-treated mice or in mice treated
with UV-inactivated virus as shown by the geometric mean
fluorescence (data not shown). By day 9 post treatment, the
activation of DC subsided and no significant difference was found
among the different groups.
Fig. 6 shows recruitment/activation of B cells in the brain,
lymph nodes and blood in mice infected and treated at the same
time (Fig. 6A) or in mice treated at 4 dpi (Fig. 6B). Significantly
more B cells were detected during the investigation period (days 3
to 9 post treatment) in the brain and lymph node and in the blood
(at days 6 and 9 post treatment) of mice treated with LBNSE-GM-
CSF than sham-treated mice or mice treated with UV-inactivated
LBNSE-GM-CSF. Taken together, our data indicate that ic
treatment with LBNSE-GM-CSF can recruit/activate more DCs
and B cells both in CNS and periphery than treatment with
medium or UV-inactivated LBNSE-GM-CSF.
Treatment with LBNSE-GM-CSF enhances the production
of virus neutralizing antibodies (VNA)
To investigate if recruitment/activation of DCs and B cells lead
to enhanced production of VNA, blood samples were collected
from mice at days 6 and 9 post treatment and VNA determined by
the RFFIT assay 20]. As shown in Fig. 6C, VNA titers were below
0.5 IU in DRV-infected and sham-treated mice at 6 and 9 dpi. In
mice infected with DRV and treated with UV-inactivated LBNSE-
GM-CSF, VNA titers were low (1.78 IU) at 6 but increased to 4.72
IU by 9 dpi (Fig. 6C). Mice treated with LBNSE-GM-CSF
produced high level of VNA both at 6 (12.01 IU) and 9 dpi
Figure 1. Protective efficacy of recombinant RABVs administrated after infection i.m. with DRV. ICR mice (group of 10) at age of 4–6
weeks were infected i.m. with 10 IMLD50 DRV, and treated with 10
7 FFU LBNSE-GM-CSF by intracerebral (A), intramuscular (B), intradermal (C) or
intranasal (D) route at different time point post infection, or treated with live or UV-inactivated LBNSE-GM-CSF at day 4 post infection (E). Infected and
treated mice were observed daily for 20 days and survivorship was recorded and analyzed. Asterisk indicates significant differences between the
indicated experimental groups as calculated by Log-rank test: *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0025414.g001
Table 1. Virus titers in the brain of mice infected im with DRV (10 IMLD50) and treated with rRABVs at 4 dpi.
Treatment Medium rRABV (GM-CSF) * UV-inactivated rRABV (GM-CSF)*
D3 -
{,- ,- 1 0
2.5,1 0
2,1 0
2.5 -, -, -
D6 10
4.5,1 0
3.5,1 0
5 -, -, - 10
4,1 0
3.5,1 0
4
D9 10
5 10
3,- ,- 1 0
5,1 0
3,1 0
4
*rRABV (GM-CSF), recombinant RABV expressing GM-CSF.
{Virus titer in the brain (FFU/g tissue).
- No virus was detected.
doi:10.1371/journal.pone.0025414.t001
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at 4 dpi, the VNA titers did not increase from day 6 to 9 post
treatment in DRV-infected and sham-treated mice (1.13 to 1.43
IU) or in mice infected with DRV and treated with UV-
inactivated LBNSE-GM-CSF (2.71 to 2.81 IU) (Fig. 6D). High
VNA titers were induced in mice treated with LBNSE-GM-CSF at
days 6 (7.36 IU) and 9 post treatment (increased to 8.48 IU)
(Fig. 6D). These data indicate that treatment with LBNSE-GM-
CSF induced significantly higher adaptive immunity as shown by
VNA titers than sham-treated mice or mice treated with UV-
inactivated LBNSE-GM-CSF. Nevertheless, treatment with UV-
inactivated LBNSE-GM-CSF also induced relatively high level of
VNA titers in the periphery.
Enhancing the BBB permeability with MCP-1 improved
the survival of mice treated with UV-inactivated LBNSE-
GM-CSF
All the above results indicate that LBNSE-GM-CSF induces the
expression of innate immune molecules, infiltration of inflamma-
tory cells into the CNS, and enhancement of BBB permeability, all
of which facilitates immune effectors enter into the CNS and
promotes viral clearance. To further confirm that expression of
cytokines/chemokines is a direct mechanism for enhancement of
BBB permeability, ICR mice were inoculated by im with
10IMLD50 DRV and then treated with medium, MCP-1
(25 mg), 10
7 FFU LBNSE-GM-CSF, UV-inactivated LBNSE-
GM-CSF (equivalent to 10
7 FFU) or a mixture of MCP-1
(25 mg) and UV-inactivated LBNSE-GM-CSF by ic at 4 dpi.
Mice were monitored daily for 20 days for developing diseases and
deaths. As shown in Fig. 7, treatment with MCP-1 alone enhanced
BBB permeability at day 2 post treatment (Fig. 7A), but did not
induce any disease while 100% of the mice infected with DRV by
im and treated with medium developed rabies and succumbed to
the infection by 14 dpi (Fig. 7B). Treatment with MCP-1 increased
the survival to 30% in mice infected with DRV, although no
significant difference was found between these two groups.
Treatment with MCP-1 increased significantly (p,0.05) the
survival rate from 10% to 50% in mice infected with DRV and
treated with UV-inactivated LBNSE-GM-CFS. As shown above,
60% of the mice infected with DRV and treated with LBNSE-
GM-CSF survived (Fig. 7B). These data indicate that enhance-
ment of BBB permeability allowed immune effectors induced by
LBNSE-GM-CSF in the periphery infiltrate into the CNS and
help clear RABV from the CNS, thereby preventing mice from
developing rabies.
Discussion
Viral infection of the CNS poses unique challenges to the
immune system with regards to controlling and eliminating the
invading pathogens. Traditionally, the CNS is considered an
immunologically privileged site 21] and the presence of a BBB
provides a physical and physiological barrier for cells and
molecules to enter into the CNS 22]. Although enhancement of
BBB permeability and infiltration of inflammatory cells have often
been associated with pathological changes in the CNS when
infected by viruses 22,23], transiently increased BBB permeability
has been found to be helpful in clearing RABV from the CNS
19,24]. Induction of an autoimmune CNS inflammatory response
resulted in increasing BBB permeability and aided RABV
clearance 19]. Expression of triple G in SPBAAN (a recombinant
RABV SAD strain) also has the ability to enhance BBB
permeability and prevent infected animals from developing rabies
25]. In the present study, we showed that direct administration of
chemokines or rRABV expressing GM-CSF into the CNS could
help clear RABV from the CNS and prevent mice infected with
street RABV from developing rabies. However, administration of
rRABV via peripheral routes is not as effective as the ic route and
this may be due to the quicker induction of proinflammatory
mediators in the CNS by direct ic administration, which impacts
the change of the BBB permeability faster than other routes of
administration.
Proinflammatory mediators such as chemokines and cytokines
have a prominent role in enhancement of the BBB permeability
during inflammatory responses 26,27,28]. In fact, expression of
chemokines early in response to infection with neurotropic viruses
aids in effective host defense by promoting vascular permeability
and regulating parenchymal lymphocyte infiltration 22]. In the
present study, chemokine alone or cytokines expressed by rRABV
are used to enhance the BBB permeability. This was based on
studies by us 13,17] and others 29,30] that laboratory-adapted
RABV induced high expression of innate immune genes
(particularly chemokines and IFN) while street RABV did not. It
is thus hypothesized that expression of chemokines and IFN is one
of the mechanisms by which RABV is attenuated 13,17]. Over-
expression of chemokines (MIP-1 alpha, RANTES, or IP-10) by
rRABV has been found to enhance BBB permeability 14]. In the
present study, it shows that over-expression of GM-CSF also
enhances the BBB permeability. It is known that expression of
chemokines/cytokines results in recruitment of inflammatory cells
into the CNS which enhances BBB permeability 22]. Indeed direct
administration of LBNSE-GM-CSF into the CNS stimulated high
level expression of chemokines/cytokines (at day 3 post treatment),
infiltration of inflammatory cells (neutrophils, activated microglia/
macrophages and T lymphocytes at day 3–9 post treatment), and
enhancement of BBB permeability (at day 6 post treatment).
Direct administration of a chemokine (MCP-1) into the CNS also
resulted in enhancement of BBB permeability, further supporting
the role of chemokines/cytokines in the enhancement of BBB
permeability.
It is apparent that enhancement of BBB permeability alone is
not sufficient to prevent mice from developing rabies since
administration of MCP-1 alone did not significantly increase the
survival of mice infected with DRV despite the fact that BBB
permeability was increased significantly in the cerebrum 2 days
after administration. We believe that this might be due to the low
RABV-specific immunity (VNA) in the mice infected with DRV
(1.13 to 1.43 IU at 10 and 13 dpi). However, administration of
MCP-1 did significantly improve protection in animals infected
with DRV and treated with UV-inactivated LBNSE-GM-CSF
(2.71 to 2.81 IU at 10-13 dpi). In fact the rate of protection (50%)
in mice treated with MCP-1 and UV-inactivated LBNSE-GM-
Figure 2. Concentration of chemokines and cytokines in the brain of mice treated with LBNSE-GM-CSF. BALB/c mice were infected with
10 IMLD50 DRV and treated at either 0 (A) or 4 (B) dpi with medium, 10
7 FFU live or UV-inactivated LBNSE-GM-CSF, brain samples were collected at
days 3, 6, and 9 post treatment. Total RNA was extracted from the brain tissue and mRNA of chemokines and cytokines was analyzed by qRT-PCR. The
mRNA copy number was normalized to the housekeeping gene GAPDH. Levels of gene expression in a test sample are presented as the fold change
over that detected in sham-infected controls. Data represent the average from three independent experiments. Asterisk indicates significant
differences between the indicated experimental groups as calculated by one-way ANOVA: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0025414.g002
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GM-CSF although the VNA titers in mice treated with the latter
(about 7 IU) are much higher. The high level of VNA induced by
LBNSE-GM-CSF is likely due to the activation of the innate
immune responses such as expression of chemokines/cytokines
and the recruitment/activation of DCs as reported previously
15,16] and demonstrated in the present study. We have
consistently observed that infection with street RABV by either
ic 13] or im 17,31] fails to stimulate the innate immune responses
while laboratory-adapted RABV induces quick and high level of
such responses including expression of innate immune molecules
in and infiltration of inflammatory cells into the CNS. Infection
with DRV stimulated the expression of innate immune genes only
at the late stage of the infection, but did not induce infiltration of
inflammatory cells. As a consequence, enhancement of BBB was
only observed at 9 dpi and only in the spinal cord. In addition, the
adaptive immune responses (VNA titers) in mice infected with
DRV are significantly lower than those in mice infected with
laboratory-adapted RABV. This is not surprising since it has been
reported that only 20% rabid patients have detectable VNA at the
time of death 32]. Roy et al 18] reported that infection with street
RABV induced similar levels of innate and adaptive immune
responses in mice as laboratory-adapted RABV. However,
infection with street RABV failed to enhance the BBB permeabil-
ity and thus the immune effectors could not gain entry into the
CNS to clear the virus. The discrepancies between these studies
could be due to differences in the virus doses used. We consistently
infect animals with 10 IMLD50 or ICLD50 13,17] and Roy et al
18] infected mice with virus titers as titrated in cell culture (FFUs).
Since we have reported that street RABV is at least 1000 times
more virulent than the laboratory-adapted RABV, and thus it
requires more virus (FFU) for laboratory-adapted RABV to kill the
infected mice 13]. Although infection with high doses of street
RABV induced comparable adaptive immunity (VNA) as the
laboratory-adapted RABV in the periphery, it may not have
stimulated chemokine expression in time to enhance the BBB
permeability. Thus, enhancement of BBB permeability and the
development of RABV-specific immunity, i.e. VNA, are the two
major factors contributing to the clearance of RABV from the
CNS and the protection of mice from developing rabies.
Over-expression of chemokines/cytokines in RABV not only
enhances the BBB permeability, but also increases the adaptive
immune responses. Previously it was found that immunization
with rRABV expressing MIP-1a, MDC, or GM-CSF induced
significantly more VNA responses in mice, which led to better
protection than with the parent virus when challenged with
virulent RABV 15,16]. The increased immunogenicity is due to
recruitment/activation of DCs. Indeed, direct ic administration of
LBNSE-GM-CSF into the CNS recruited/activated DCs in the
periphery. Not only significantly more CD11c+ cells, but also
higher geometric mean fluorescence of the CD80 and CD86
expression, were detected in the lymph nodes and blood of mice
treated with LBNSE-GM-CSF than in sham-treated mice or in
mice treated with UV-inactivated LBNSE-GM-CSF. Recruit-
ment/activation of DCs resulted in significantly more activation of
B cells in the CNS of mice treated with LBNSE-GM-CSF than in
sham-treated mice or mice treated with UV-inactivated LBNSE-
GM-CSF. It has been hypothesized that it is the VNA produced in
situ (CNS) by invading B cells, rather than those produced in the
periphery and then transported into the CNS, that are protective
33]. In our study, direct ic administration of UV-inactivated
LBNSE-GM-CSF did not provide better protection than sham-
treatment despite the fact that VNA was induced in the periphery.
Very few B cells were detected in the CNS. However, treatment
with UV-inactivated LBNSE-GM-CSF together with administra-
tion of MCP-1 improved the rate of survival to the level similar to
Figure 3. Differentiation of inflammatory cells infiltrated into CNS by flow cytomeric analyses. BALB/c mice were infected i.m. with 10
IMLD50 DRV and were treated at either 0 or 4 dpi with medium, 10
7 FFU live or inactivated LBNSE-GM-CSF. Leukocytes from CNS were recovered by
Percoll centrifugation and stained with cell surface markers CD11b (Microglia/macrophage), Ly6G (Neutrophils) and CD3 (T cells). The stained cells
were analyzed by flow cytometry. Representative flow cytometric plots of infiltrated cells in mouse brain at day 6 post treatment for each of the
treatment groups (A). The absolute numbers of indicated inflammatory cells in the brain were presented for mice treated at day 0 (B) or 4 (C) dpi,
respectively. All data are from n=3 mice per group. Asterisk indicates significant differences between the indicated experimental groups as
calculated by one-way ANOVA: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0025414.g003
Figure 4. Induction of BBB permeability after treatment with
LBNSE-GM-CSF. Mice were treated with medium or 10
7 FFU LBNSE-
GM-CSF at 0 (A) or 4 (B) dpi. BBB permeability was determined by
uptake of sodium fluorescein at day 6 post treatment. Data are given as
mean values + SEM. Asterisks indicate significant differences between
the indicated experimental groups: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0025414.g004
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whether administration of MCP-1 allowed VNA and/or B cells
enter into the CNS and thus future studies are warranted.
Traditional inactivated RABV vaccines have been used for pre-
and post-exposure prophylaxis for humans with high safety and
efficacy 34,35,36]. However, multiple doses are needed to
stimulate adequate immunity, thus driving up the cost and
preventing wide distribution of these vaccines, particularly in the
developing countries 2]. Furthermore, inactivated RABV vaccines
cannot be used for delayed treatment since they may accelerate
the development of rabies 12]. Live attenuated RABV and
recombinant live vaccinia virus expressing RABV G (VRG) have
been so far limited to immunization of wildlife animals 37,38,39].
Recently, it has been shown that live-attenuated RABV,
particularly those expressing multiple copies of RABV G or
immune stimulating molecules, can further attenuate viral
virulence and at the same time enhance the immunogenicity
14,15,16,25,40], suggesting that live-attenuated RABV (expressing
multiple copies of the G or immune stimulatory molecules) could
be developed as RABV vaccines for pre- and post-exposure
prophylaxis. Indeed, Wu et al (34) reported that co-administration
of live-attenuated RABV and street RABV can protect mice and
hamsters from developing rabies. Furthermore, Faber et al (24)
reported that 50% of the mice survived the infection with a street
RABV when given a recombinant RABV expressing three copies
of the G as late as 4 dpi. In this study, significantly more mice were
protected when recombinant RABV expressing GM-CSF was
given as late as 5 dpi. Most importantly, these live recombinant
RABV can enhance the BBB permeability, allowing innate as well
as RABV-specific immunity to enter the CNS to clear RABV as
shown previously (24) as well as in this present study. Therefore,
these commodities may have practical implications in treatment of
clinical rabies. Further studies are needed to address if such
treatment is effective at the time of clinical diseases in a more
suitable animal model.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animalsof the National Institutes of Health.Allanimalexperiments
Figure 5. Recruitment/activation of DCs in the lymph node and periphery blood of mice treated with LBNSE-GM-CSF. BALB/c mice
were infected with 10 IMLD50 DRV and treated at 0 (A) or 4 (B) dpi with medium, 10
7 FFU live or inactivated LBNSE-GM-CSF. At days 3, 6, and 9 post
treatment, single cell suspensions were prepared from inguinal lymph node or peripheral blood and stained with antibodies against surface markers
of DCs (CD11c+). The stained cells were analyzed by flow cytometry. All data are from n=3 mice in each group and presented as mean values 6
standard errors (SE). Asterisk indicates significant differences between the indicated experimental groups as calculated by one-way ANOVA: *, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0025414.g005
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Use Committee, University of Georgia (AUP # A2009 5–103,
animal welfare assurance no. A3085-01). All efforts were made to
minimize animal suffering.
Cells, viruses, antibodies, and animals
BSR cells, a cloned cell line derived from BHK-21, were
maintained in Dulbecco’s modified Eagle’s medium (Mediatech,
Herndon, VA) supplemented with 10% fetal bovine serum (FBS)
(Gibco, Grand Island, NY). Mouse neuroblastoma cells (NA) were
maintained in RMPI 1640 medium (Mediatech) containing 10%
FBS. Recombinant RABV expressing GM-CSF (LBNSE-GM-
CSF) was constructed as described 16]. Street RABV (DRV) 41]
(Mexico-origin, data not published) was propagated in suckling
mouse brains. Challenge virus standard (CVS)-11 was propagated
in NA cells. Fluorescein isothiocyanate (FITC)-conjugated anti-
body against the RABV N protein was purchased from Fujirebio
(Melvin, PA). Antibodies used for flow cytometric analysis, such as
Figure 6. Recruitment/activation of B cells in the CNS and the periphery and the production of VNA in mice treated with LBNSE-
GM-CSF. BALB/c mice were infected with 10 IMLD50 DRV and treated at 0 (A, C) or 4 (B, D) dpi with medium, 10
7 FFU live or inactivated LBNSE-GM-
CSF. Brain, lymph node and peripheral blood were harvested at days 3, 6, and 9 post treatments. Leukocytes recovered from CNS by Percoll
centrifugation or signal-cell suspensions prepared from the lymph node or peripheral blood were stained with antibodies against B cell markers
(CD40 and CD19). The stained cells were analyzed by flow cytometry. The number of B cells in the brain and the percentage of mature B cells in the
lymph node or blood were presented in mice treated at 0 (A) or 4 (B) dpi. Blood samples were collected at days 6 and 9 post treatment and VNA titers
determined by RFFIT (C for VNA in mice treated at 0 and D at 4 dpi). All data are from n=3 mice in each group and presented as mean values +
standard errors (SE). Asterisk indicates significant differences between the indicated experimental groups as calculated by one-way ANOVA: *, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0025414.g006
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(clone 30-F11), anti-CD11b (clone M1/70), anti-CD11c (clone
HL3), anti-CD80 (clone 16-10A1), anti-CD86 (clone GL1) and
anti-CD40 (clone 3/23) were purchased from BD Pharmingen
(San Jose, CA). Anti-CD19 antibody (clone 1D3) was purchased
from eBioscience (San Diego, CA). Recombinant murine MCP-1
was purchased from PreproTech (Rocky Hill, NJ). Female BALB/
c and ICR mice were purchased from Harlan and housed in
temperature- and light-controlled quarters in the Animal Re-
sources Facility, College of Veterinary Medicine, University of
Georgia. At indicated time points, mice were anesthetized with
ketamine-xylazine at a dose of 0.1 ml/10 g body weight and then
perfused by intracardiac injection of PBS followed by 10% neutral
buffered formalin as described previously 42]. Brain tissues were
collected for respective studies.
Virus titration
Mouse brains were homogenized in phosphate-buffered saline
(PBS) (10 ml/g tissue). After homogenization and centrifugation,
the supernatants were harvested, aliquoted and stored at -80uC
until use. Viruses were titrated by direct fluorescent antibody assay
(dFA) in NA cells. NA cells in 96-well plate were inoculated with
serial 10-fold dilutions of supernatant and incubated at 34uC for 2
days. The culture supernatant was removed and the cells were
fixed with 80% ice-cold acetone for 30 min. The cells were then
stained with FITC-conjugated anti-RABV N antibodies. Antigen-
positive foci were counted under a fluorescent microscope (Zeiss,
Germany) and viral titers were calculated as fluorescent focus units
(FFU) per milliliter. All titration were carried out in quadruplicate.
Quantitative real-time RT-PCR (qRT-PCR)
To quantify the expression of chemokines/cytokines, a real time
SYBR Green PCR assay was carried out in an Mx3000P
apparatus (Stratagene, La Jolla, CA). Brain tissues were removed
from infected mice after perfusion at indicated time points, and
flash frozen on dry ice before being stored at 280uC. Total RNA
was extracted with Trizol and used for qRT-PCR as described
previously 13]. Each reaction was carried out in duplicate with
approximately 100 ng of DNase-treated RNA and 5 nM each
primer pairs described previously 13] by using a One-Step
Brilliant II SYBR green qRT-PCR master mix kit (Stratagene, La
Jolla, CA) according to the manufacturer’s instruction. For
chemokines/cytokines expression, mRNA copy numbers of a
particular gene were normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Levels of
gene expression in a test sample are presented as the fold increase
over that detected in sham-infected controls.
Measurement of BBB permeability
BBB permeability was measured using a modification of a
previously described technique in which a low-molecular-weight
fluorescent marker (Sodium fluorescein; molecular weight, 376) is
utilized as a tracer molecule 24]. Briefly, mice received 100 mlo f
100 mg/ml sodium fluorescein intravenously under anesthesia.
After 10 min circulation for sodium fluorescein, peripheral blood
was collected and mice were perfused with PBS for 10 min. Serum
(50 ml) was recovered and mixed with an equal volume of 15%
trichloroacetic acid (TCA). After centrifugation for 10 min at
10,0006g, the supernatant was harvested. Spinal cord or brain
tissues were homogenized in 7.5% TCA and centrifuged for
10 min at 10,0006g to remove insoluble precipitates. After the
addition of 30 ml 5 M NaOH to 120 ml supernatant, the
fluorescence was determined using a BioTek Spectrophotometer
(Bio-Tek Instruments Inc, Winooski, VT) with excitation at
485 nm and emission at 530 nm. Sodium fluorescein taken up
into tissue is expressed as (mg fluorescence in cerebrum/mg tissue)/
(mg fluorescence/ml sera) to normalize uptake values of the dye for
blood levels of the dye at the time of tissue collection.
Leukocyte isolation from CNS, lymph nodes, and the
blood for flow cytometry
Mouse brains were harvested and digested with 1 mg/ml DNase
I (Sigma-Aldrich), 2 mg/ml collagenase D (Worthington Biochem-
ical Corporation, Lakewood, NJ) in Hanks balanced salt solution
Figure 7. Enhancement of BBB permeability induced by MCP-1
improves protection in mice treated with UV-inactivated
rRABV. Mice were treated with medium or MCP-1 (25 mg) by ic, BBB
permeability was determined by uptake of sodium fluorescein at day 2
post treatment (A). ICR mice (group of 10) at age of 4–6 weeks were
infected i.m. with 10 IMLD50 DRV, and then treated with medium, MCP-
1( 2 5 mg), 10
7 FFU LBNSE-GM-CSF, UV-inactivated LBNSE-GM-CSF
(equivalent to 10
7 FFU) or a mixture of MCP-1 (25 mg) and UV-
inactivated LBNSE-GM-CSF (equivalent to 10
7 FFU) by ic at day 4 post
infection. The mice were observed for 20 days post infection, and
survivorship was recorded and analyzed. Asterisk indicates significant
differences between the indicated experimental groups as calculated
by one-way ANOVA or Log-rank test: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0025414.g007
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2+ and Mg
2+) for 1 h to disperse the tissue into single-cell
suspension. Viable cells were separated by discontinuous Percoll
gradient (70/30%) centrifugation (6506g, 25 min). After being
washed once with Hanks balanced salt solution (without Ca
2+ and
Mg
2+) and counted, cells were stained for antibodies against CD3,
Ly6G, CD45, CD11b and CD19 at 4uC for 30 min and then fixed
with 1% paraformaldehyde for flow cytometry.
Cervical lymph nodes and blood were collected and red blood
cells were lysed by ammonium chloride lysing solution (150 mM
NH4Cl, 10 mM NaHCO3, 1 mM EDTA). Single-cell suspensions
were then prepared at 10
6 cells in PBS containing 2% FBS and
0.1% NaN3 and stained with antibodies against CD40, CD19,
CD11b, CD11c, CD80 and CD86 for 30 min at 4uC. Data were
acquired on LSR-II flow cytometer (BD Bioscience), and analyzed
using BD FACSDiva (BD Pharmingen) or FlowJo software (Tree
Star).
Rapid fluorescent focus inhibition test (RFFIT)
Blood was collected for measurement of VNA using the RFFIT
as described previously 20]. Briefly, 50 ml of serial five-fold
dilutions of serum were prepared in Lab-Tek Chamber slides
(Nalge Nunc International, Rochester, NY). Fifty FFD50 (50%
Fluorescing Foci dose) of CVS-11 was added to each chamber and
incubated for 90 min at 37uC. NA cells (10
5 cells) were added into
each chamber and the slides were incubated at 37uC for 20 hr.
Then the cells were fixed with ice-cold 80% acetone and stained
with FITC-conjugated anti-RABV N antibodies for 1 hr at 37uC.
Twenty fields in each chamber were observed under a fluorescent
microscope, and the 50% endpoint titers were calculated
according to the Reed-Meunch formula 43]. The values were
compared with that of the reference serum (obtained from the
National Institute for Biological Standards and Control, Herts,
UK) and normalized to international units (IU/ml).
Statistical Analyses. Statistical significance of the differences
between groups was determined using one-way ANOVA or Log-
rank test.
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